Ruzurgi® (amifampridine), indicated for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in patients 6 years of age or older, is an oral potassiumchannel inhibitor designed to prolong signals released from nerves to allow greater stimulation of muscle.
Ruzurgi® (amifampridine), indicated for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in patients 6 years of age or older, is an oral potassiumchannel inhibitor designed to prolong signals released from nerves to allow greater stimulation of muscle.